Rediff.com India Ltd. (Nasdaq:REDF) announces the results of its Extra-ordinary General Meeting (EGM) of its shareholders held on November 26, 2010. At the EGM, Rediff’s shareholders unanimously approved all 3 resolutions presented for vote, including the resolution relating to the acquisition of Vubites. The acquisition is expected to be completed before December 10, 2010 and once completed will enable the Company to enter the Local TV-Ad market using internet technology.
Rediff.com (NASDAQ:REDF) is one of the premier worldwide online providers of news, information, communication, entertainment and shopping services to Indians worldwide. Founded in 1996, Rediff.com is headquartered in Mumbai, India with offices in New Delhi, India and New York, USA.
Power3 Medical Products, Inc. (OTC:PWRM)
PWRM recently filed several patent applications that are currently pending for its NuroPro technology. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China. PWRM has also published 6 articles on NuroPro in peer-reviewed scientific journals. PWRM intends to publish these latest findings as well.
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. PWRM’s products analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
To learn more about PWRM visit: http://www.Power3Medical.com
NetSol Technologies, Inc. (Nasdaq:NTWK) - Atheeb NetSol Saudi Company Ltd., NetSol's joint venture with business conglomerate Atheeb Group Ltd., is participating in the 2nd Annual Kingdom Healthcare Expansion and Investment Summit today, at the Park Hyatt Jeddah in Jeddah, Kingdom of Saudi Arabia.
The two-day summit, endorsed by the Kingdom of Saudi Arabia's Ministry of Health, will unite government representatives, decision makers, investors and solution providers to discuss the future of healthcare in Saudi Arabia, the largest healthcare market in the Middle East. Atheeb NetSol is a Bronze-level sponsor of the event and will exhibit its offerings, including NetSol's Hospital Management Information System software solution, during the summit.
NetSol Technologies, Inc. (Nasdaq:NTWK) is a worldwide provider of global IT and enterprise application solutions. Since its inception in 1995, NetSol has used its BestShoring(NYSE:TM) practices and highly experienced resources in analysis, development, quality assurance, and implementation to deliver high-quality, cost-effective solutions.
Orofino Gold Corp. has several Gold development properties in Colombia, a current hot spot of gold production in the world markets. Orofino Gold is please to report that the Board Of Directors have appointed Mr. Ning Shi Long as Chairman of the Board and Executive Director. Mr. Ary Fernando Pernett Marque has been appointed as the new President/CEO & Executive Director of Orofino Gold Corp.
Mr. Pernett will be responsible for all affairs of Orofino Gold in Colombia. Mr. Pernett has 30 years of experience working in the Colombian Mining sector and will over the near term choose his new development team to assist in the development of Orofino Gold’s Senderos de Oro gold camp in the Sur de Bolivar Colombia.
The new team will now aggressively pursue other known Gold occurrences in the companies Senderos de Oro Gold Camp while the development team works to improve production at La Azul Mine. The Board of Director’s have accepted resignation of John T. Martin, former Managing Director of Orofino Gold. His resignation is effective immediately. Orofino Gold wish him well and success in future endeavors.
Orofino Gold and Mr. Pernett will continue to work with Contexto Legal of Medellin and Bogota, Orofino Gold’s legal counsel as well as Discovery Consultants, (The Qualified 43-101 team) Canada, as they have in the past.
Orofino Gold Corp. engages in acquisition, exploration, and development of gold properties in Mexico and Colombia. Orofino Gold has an option to acquire properties in the Sur de Bolivar Department of Colombia South America.
To learn about ORFG visit: http://www.orofinogold.com
Geron Corporation (Nasdaq:GERN) announced on December 2, 2010 enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or without bevacizumab) in patients with locally recurrent or metastatic breast cancer.
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple Phase 2 clinical trials in different cancers.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).